{"id":"NCT01691859","sponsor":"GlaxoSmithKline","briefTitle":"MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects","officialTitle":"MEA115666: A Multi-centre, Open-label, Long Term Safety Study of Mepolizumab in Asthmatic Subjects Who Participated in the MEA112997 Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-09-28","primaryCompletion":"2017-05-31","completion":"2017-05-31","firstPosted":"2012-09-25","resultsPosted":"2018-05-22","lastUpdate":"2023-06-28"},"enrollment":347,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"Mepolizumab","otherNames":[]}],"arms":[{"label":"Mepolizumab","type":"EXPERIMENTAL"}],"summary":"This is a multi-centre, open-label long term safety study of 100 milligrams (mg) mepolizumab administered subcutaneously (SC) in addition to standard of care in subjects who participated in the MEA112997 study. At each clinic visit, adverse events will be assessed and exacerbations will also be reviewed.","primaryOutcome":{"measure":"Number of Participants Who Experienced On-treatment Adverse Events (AE) and On-treatment Serious Adverse Events (SAE)","timeFrame":"Baseline (Week 0) to Week 240","effectByArm":[{"arm":"Mepolizumab 100 mg","deltaMin":326,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":9},"locations":{"siteCount":64,"countries":["United States","Argentina","Australia","Canada","Chile","France","Germany","Poland","Romania","Russia","South Korea","Ukraine","United Kingdom"]},"refs":{"pmids":["30359681","30954640"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":79,"n":347},"commonTop":["Viral upper respiratory tract infection","Headache","Upper respiratory tract infection","Bronchitis","Asthma"]}}